i-Lumen Scientific Receives FDA Approval of IDE to Initiate U.S. Enrollment in i-SIGHT2 Clinical Study for dry AMD

IDE approval by the FDA expands global trial to the United States as first study participant is treated in the United Kingdom BLOOMINGTON, Minn., March 31, 2026 /PRNewswire/ -- i-Lumen Scientific, Inc., a leader in energy-based innovations for ophthalmology, and its non-invasive...